ARS Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30.0K | $1.3M | $5.5M |
| Cost of Revenue | — | — | $0 | — | — |
| Gross Profit | — | — | $30.0K | — | — |
| Gross Margin | — | — | 100.0% | — | — |
| Operating Expenses | |||||
| Research & Development | $13.2M | $19.6M | $20.3M | $18.4M | $20.3M |
| SG&A Expense | $230.1M | $71.7M | $47.3M | $603.0K | $4.7M |
| Operating Income | $-179.4M | $-3.1M | $-67.5M | $-35.5M | $-19.5M |
| Operating Margin | -212.9% | -3.5% | -225,066.7% | -2,698.8% | -353.3% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-171.4M | $8.3M | $-54.4M | — | — |
| Income Tax Expense | $-80.0K | $288.0K | $0 | $0 | $0 |
| Net Income | $-171.3M | $8.0M | $-54.4M | $-34.7M | $-20.2M |
| Net Margin | -203.3% | 9.0% | -181,216.7% | -2,635.4% | -367.7% |
| EPS (Basic) | $-1.74 | $0.08 | $-0.57 | $-0.44 | $-0.35 |
| EPS (Diluted) | $-1.74 | $0.08 | $-0.57 | $-0.44 | $-0.35 |
| Shares Outstanding (Basic) | 98.6M | 96.9M | 95.2M | 79.9M | 57.7M |
| Shares Outstanding (Diluted) | 98.6M | 102.4M | 95.2M | 79.9M | 57.7M |
| Dividends Per Share | — | — | — | — | — |